Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 10/20 | 0.40 |
| ▸ | CNR2 | P34972 | 10/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823389 | 0.85 | MEN1 (0.44) | MEN1KMT2AHSD17B10KDM4EMAPT | |
| SCHEMBL823338 | 0.85 | MEN1 (0.51) | MEN1KMT2AHSD17B10MAPTHPGD | |
| SCHEMBL826802 | 0.83 | KDM5A (0.52) | MEN1KMT2AHSD17B10KDM4EMAPT | |
| SCHEMBL823360 | 0.82 | HSD17B10 (0.45) | MEN1KMT2AHSD17B10KDM4EMAPT | |
| SCHEMBL823557 | 0.73 | MEN1 (0.44) | MEN1KMT2AHPGDCNR1CNR2 | |
| SCHEMBL823344 | 0.72 | NPC1 (0.43) | MEN1KMT2AKDM4EMAPTHPGD | |
| SCHEMBL823335 | 0.72 | SMN1; SMN2 (0.43) | KMT2AKDM4EMAPTHPGDALDH1A1 | |
| SCHEMBL823362 | 0.71 | CNR1 (0.45) | MEN1KMT2AHPGDTSHRCNR1 | |
| SCHEMBL823456 | 0.71 | NR1I3 (0.52) | MEN1KMT2AHSD17B10KDM4EMAPT | |
| SCHEMBL5647057 | 0.71 | CNR1 (0.42) | MEN1KMT2AHPGDTSHRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143268-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-03-27 | — | — | US | disclosed |
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168063-A1 | BICYCLIC PYRIMIDINONES AND USES THEREOF | TPMT, TYMP, DPYD | MEN1 1774/4885KMT2A 2241/4885HSD17B10 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.